IKZF3 Antibody [D19G22] | Primary Antibodies

Application: Reactivity: Mouse, Rat, Human

Lane 1: Raji, Lane 2: Ramos, Lane 3: Jurkat

Usage Information

Dilution
WB1:20000 IHC1:50 - 1:100 IF1:100 FCM1:10 - 1:100

Application
WB, IHC, IF, FCM

Reactivity
Mouse, Rat, Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
58 kDa 70 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Positive Control	Human spleen tissue; Mouse cardiac muscle tissue; Rat spleen tissue; Human thymus cells; Jurkat cells; Raji cells; Ramos cells
Negative Control

Datasheet & SDS

Biological Description

Specificity
IKZF3 Antibody [D19G22] detects endogenous levels of total IKZF3 protein.

Clone
D19G22

Synonym(s)
ZNFN1A3; IKZF3; Zinc finger protein Aiolos; Ikaros family zinc finger protein 3

Background
IKZF3 (Aiolos) is a hematopoietic-specific zinc finger transcription factor from the Ikaros family, essential for B-cell development and effector maturation. It contains an N-terminal DNA-binding domain with four tandem C2H2 zinc fingers that recognize the core GGAAA motif, particularly through major groove contacts made by key arginine and histidine residues, and a C-terminal dimerization domain with two additional zinc fingers that enable homo- and heterodimerization with other Ikaros proteins such as IKZF1 (Ikaros), IKZF2 (Helios), and IKZF4 (Eos), facilitating both repressive and activating transcriptional complexes. IKZF3 orchestrates sequential B-cell programming: initial IKZF1 homodimers establish lymphoid priming, while IKZF1:IKZF3 heterodimers recruit chromatin remodeling and co-repressor complexes such as NuRD, SWI/SNF, and PRC2 to silence pro-apoptotic genes and enforce survival checkpoints. As B cells mature, IKZF3 homodimers activate key regulators like BLIMP1, STAT3, and XBP1 to drive plasma cell differentiation and antibody secretion. In regulatory T cells, IKZF3 modulates IL-10 expression indirectly through synergy with FOXP3. Germline dominant-negative IKZF3 variants can interfere with IKZF1 function, repressing genes involved in B and T cell homing and leading to immunodeficiency, while somatic overexpression of IKZF3 sustains aberrant BCR and IL-7R signaling in leukemias.

Background

IKZF3 (Aiolos) is a hematopoietic-specific zinc finger transcription factor from the Ikaros family, essential for B-cell development and effector maturation. It contains an N-terminal DNA-binding domain with four tandem C2H2 zinc fingers that recognize the core GGAAA motif, particularly through major groove contacts made by key arginine and histidine residues, and a C-terminal dimerization domain with two additional zinc fingers that enable homo- and heterodimerization with other Ikaros proteins such as IKZF1 (Ikaros), IKZF2 (Helios), and IKZF4 (Eos), facilitating both repressive and activating transcriptional complexes. IKZF3 orchestrates sequential B-cell programming: initial IKZF1 homodimers establish lymphoid priming, while IKZF1:IKZF3 heterodimers recruit chromatin remodeling and co-repressor complexes such as NuRD, SWI/SNF, and PRC2 to silence pro-apoptotic genes and enforce survival checkpoints. As B cells mature, IKZF3 homodimers activate key regulators like BLIMP1, STAT3, and XBP1 to drive plasma cell differentiation and antibody secretion. In regulatory T cells, IKZF3 modulates IL-10 expression indirectly through synergy with FOXP3. Germline dominant-negative IKZF3 variants can interfere with IKZF1 function, repressing genes involved in B and T cell homing and leading to immunodeficiency, while somatic overexpression of IKZF3 sustains aberrant BCR and IL-7R signaling in leukemias.

References
https://pubmed.ncbi.nlm.nih.gov/38216003/ https://pubmed.ncbi.nlm.nih.gov/37662955/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%